Drug Recalls: Is Avandia Next?
On July 16, 2010, the Food and Drug Administration (FDA) decided to keep the diabetes drug Avandia (rosiglitazone) on the market despite a cardiovascular threat to some patients. Conflicting studies have shown that the drug rosiglitazone promotes increased cardiovascular risk to patients with diabetes. The FDA, as well as the Endocrine Society, the American Association of Clinical Endocrinologists and the American Diabetes Association, have issued warnings that stopping the...
Read More